A Phase I/II Clinical Study of Chimeric Antigen Receptor T-cell Therapy Targeting CD19 and BCMA (GC012F) in Patients With Relapsed/Refractory Multiple Myeloma
Latest Information Update: 20 Mar 2024
At a glance
- Drugs AZD 0120 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gracell Biotechnology
Most Recent Events
- 23 Jan 2024 Status changed to recruiting.
- 13 Nov 2023 According to a Gracell Biotechnology media release, trial is expected to initiate in the fourth quarter of 2023.
- 26 Sep 2023 According to a Gracell Biotechnology media release, the company plans to commence this trial imminently.